Creative Planning
HRTX icon

Creative Planning’s Heron Therapeutics HRTX Stock Holding History

Creative Planning’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.3K Buy
+35,862
New +$28.8K ﹤0.01% 4207
2025
Q4 		– Sell
-12,409
Closed -$15.6K – 3992
2025
Q3 		$15.6K Sell
12,409
-26,980
-68% -$42.8K ﹤0.01% 3825
2025
Q2 		$81.5K Sell
39,389
-59,063
-60% -$121K ﹤0.01% 3456
2025
Q1 		$217K Buy
+98,452
New +$191K ﹤0.01% 2998
2017
Q3 		– Sell
-2,149
Closed -$30K – 2703
2017
Q2 		$30K Buy
2,149
+149
+7% +$2.16K ﹤0.01% 2883
2017
Q1 		$30K Buy
+2,000
New +$27.7K ﹤0.01% 2835

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Creative Planning's HRTX Position: Q2 2026 in Review

Creative Planning opened a new position in Heron Therapeutics (HRTX) in Q2 2026: 35,862 shares worth $15.3K. The stake represents ﹤0.01% of the portfolio and ranks #4207 among its holdings. This is a return to the name: Creative Planning previously reported a position in HRTX as recently as Q3 2025.

Creative Planning first reported a position in HRTX in Q1 2017 and has held it in 6 quarters since. The position peaked at $217K in Q1 2025. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Creative Planning held 35,862 shares of Heron Therapeutics worth $15.3K as of Q2 2026.
  • Heron Therapeutics was a new Creative Planning position in Q2 2026.
  • Heron Therapeutics made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #4207 holding.
  • Creative Planning first reported a position in Heron Therapeutics in Q1 2017 and has held it in 6 quarters since.
  • Creative Planning's Heron Therapeutics position peaked at $217K in Q1 2025.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.